2025/12/04
薬効解析のためのPDXZ移植部位PVS (Perivitelline Space: 卵黄周囲腔)
2025/12/04
PDXZ移植部位Perivitelline Space(PVS)卵黄嚢の特徴
2025/12/04
AIプレシジョン患者がん移植ゼブラフィッシュシステム(PDXZ)セミナー
2025/12/04
2026年1月21日(水)13:00-16:30AIプレシジョンPDXZセミナー
2025/12/02
prospective clinical PDXZ researchのインパクト
Oncocardiology is a subspecialty of cardiology that focuses on the prevention, diagnosis and treatment of cardiovascular complications caused by cancer therapies. Sorafenib is a tyrosine kinase inhibitor that is used to treat advanced hepatocellular carcinoma and renal cell carcinoma. However, sorafenib can also induce cardiotoxicity, such as hypertension, left ventricular dysfunction, heart failure and ischemia. The characterization of oncocardiology of sorafenib involves the identification of risk factors, biomarkers and imaging modalities that can help to monitor and manage the cardiac effects of this drug. Additionally, the characterization of oncocardiology of sorafenib requires the development of strategies to prevent or mitigate cardiotoxicity, such as dose adjustment, drug interruption or discontinuation, and the use of cardioprotective agents.